A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.
There is a critical need to non-invasively and remotely manipulate cells at a distance, particularly for translational applications in animals and humans, researchers said.
The team developed an innovative approach to use mechanogenetics—a field of science that focuses on how physical forces and changes in the mechanical properties of cells and tissues influence gene expression—for the remote control of gene and cell activations. Researchers used ultrasound to mechanically perturb T cells, and then converted the mechanical signals into genetic control of cells.
In this study, researchers show how their remote-controlled mechanogenetics system can be used to engineer chimeric antigen receptor (CAR)-expressing T cells that can target and kill cancer cells. The engineered CAR-T cells have mechano-sensors and genetic transducing modules that can be remotely activated by ultrasound via microbubble amplification.
“CAR-T cell therapy is becoming a paradigm-shifting therapeutic approach for cancer treatment,” said bioengineering professor Peter Yingxiao Wang at the University of California San Diego. “However, major challenges remain before CAR-based immunotherapy can become widely adopted. For instance, the non-specific targeting of CAR-T cells against nonmalignant tissues can be life-threatening. This work could ultimately lead to an unprecedented precision and efficiency in CAR-T cell immunotherapy against solid tumors, while minimizing off-tumor toxicities.”
The team brings together the laboratories of professors Wang and Shu Chien, both bioengineering professors at the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego, in collaboration with professors Kirk Shung of the University of Southern California and Michel Sadelain at Memorial Sloan Kettering Cancer Center in New York. Researchers present their findings in the Jan. 15 issue of the Proceedings of the National Academy of Sciences, with UC San Diego Ph.D. candidate Yijia Pan as the first author.
Researchers found that microbubbles conjugated to streptavidin can be coupled to the surface of a cell, where mechanosensitive Piezo1 ion channels are expressed. Upon exposure to ultrasound waves, microbubbles vibrate and mechanically stimulate Piezo1 ion channels to let calcium ions inside the cell. This triggers downstream pathways, including calcineurin activation, NFAT dephoshorylation and translocation into the nucleus. The nucleus-translocated NFAT can bind to upstream response elements of genetic transducing modules to initiate gene expression of chimeric antigen receptor (CAR) for the recognition and killing of target cancer cells.
The Latest on: CAR-T cell therapy
[google_news title=”” keyword=”CAR-T cell therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapyon November 28, 2023 at 2:56 pm
The FDA has launched an investigation into reports of T-cell malignancies in patients treated with autologous chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA ...
- FDA investigating cancer risk tied to CAR-T cell therapyon November 28, 2023 at 1:29 pm
The agency said the benefit of approved treatments like Gilead’s Yescarta still outweighs any such risk, but the alert could slow drugmaker efforts to develop the treatments for wider use.
- FDA Investigating Reports of T-cell Malignancies Following CAR T-cell Therapyon November 28, 2023 at 10:57 am
The announcement applies to all currently approved therapies, both BCMA-directed and CD19-directed genetically modified autologous CAR T-cell treatments.
- FDA investigating serious risk of T-cell malignancies in CAR-T cell therapy patientson November 28, 2023 at 9:22 am
The U.S. Food and Drug Administration (FDA) on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies directed towards the ...
- FDA investigates 'serious risk' of secondary cancer following CAR-T treatmenton November 28, 2023 at 9:16 am
In a blow to CAR-T therapies, the FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs. | In a blow to CAR-T therapies, ...
- CAR T Cell Immunotherapy And The Quiet Hope For A Universal Cancer Treatmenton November 27, 2023 at 10:00 am
All of us have to deal with the looming threat of developing cancer during our lifetime, no matter how good our genetics are, or how healthy our lifestyle is. Despite major improvements to the way ...
- Living therapieson November 23, 2023 at 4:01 pm
CAR T-cell treatment is a custom immunotherapy that involves extracting immune cells (called T-cells) from a patient, genetically engineering them with a virus to enhance their cancer-killing ...
- ‘Time bomb’ cancer treatment could blow the ‘doors’ off tumour cells in major scientific breakthrough, experts sayon November 23, 2023 at 7:23 am
SCIENTISTS have discovered a way to blow the “doors” off cancer cells for the first time, a study shows. The new method triggers a “time bomb” in tumours that could open them up to new treatment, ...
- Opinion: CAR T-cell therapy delays jeopardize lives of Canadians with blood canceron November 22, 2023 at 5:27 am
Blood cancers represent 10 per cent of all cancer cases in Canada and affect people of all ages. It is the third leading cause of cancer-related deaths in Canada. CAR T-cell therapies have changed the ...
- Promising CAR T Cell Target Helps Cancer Trick the Immune Systemon November 22, 2023 at 2:30 am
A newly identified target for CAR T-cell therapy could open doors for CAR T therapy for solid cancers, after the resistance mechanism was identified.
via Google News and Bing News